LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects

Background: This study aimed to investigate the pharmacokinetics, safety, and immunogenicity of recombinant humanized anti-human IL-6R monoclonal antibody injection, LZM008, and evaluate the pharmacokinetic similarity between LZM008 and tocilizumab (ACTEMRA®) in Chinese healthy male subjects.Researc...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Guoying Cao, Jingjing Wang, Jinjie He, Yingying Hu, Haijing Yang, Linling Que, Xianghong Gu, Jicheng Yu, Xiaojie Wu, Jufang Wu, Wei Fang, Qing He, Jing Zhang
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-04-01
Serija:	Frontiers in Pharmacology
Teme:	biosimilar tocilizumab pharmacokinetics immunogenicity safety
Online dostop:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1111893/full
Oznake:	Označite Brez oznak, prvi označite!